57.06
price down icon3.91%   -2.32
after-market アフターアワーズ: 57.06
loading
前日終値:
$59.38
開ける:
$59.77
24時間の取引高:
2.53M
Relative Volume:
2.68
時価総額:
$1.95B
収益:
$55.63M
当期純損益:
$-158.10M
株価収益率:
-6.7766
EPS:
-8.4202
ネットキャッシュフロー:
$-203.94M
1週間 パフォーマンス:
-14.96%
1か月 パフォーマンス:
-23.88%
6か月 パフォーマンス:
-20.84%
1年 パフォーマンス:
+2.59%
1日の値動き範囲:
Value
$57.04
$60.98
1週間の範囲:
Value
$56.21
$69.84
52週間の値動き範囲:
Value
$33.40
$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1067)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
63
Name
Twitter
@nektarnews
Name
次回の収益日
2026-11-05
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NKTR icon
NKTR
Nektar Therapeutics
57.06 1.95B 55.63M -158.10M -203.94M -8.4202
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-24 開始されました Wedbush Neutral
2026-03-17 開始されました TD Cowen Buy
2026-02-10 アップグレード William Blair Mkt Perform → Outperform
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
02:26 AM

Nektar Therapeutics Director Roy Whitfield Reports Acquisition of RSUs and Stock Options - Kalkine Media

02:26 AM
pulisher
12:56 PM

Form 4 Nektar Therapeutics For: 25 September By Investing.com - Investing.com Nigeria

12:56 PM
pulisher
Sep 25, 2026

Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

A director receives 2,000 stock units alongside 4,000 options at Nektar Therapeutics (NKTR). - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Director Robert Chess also received 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Director Diana Brainard receives 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly By Investing.com - Investing.com South Africa

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - prnewswire.com

Sep 25, 2026
pulisher
Sep 25, 2026

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters

Sep 25, 2026
pulisher
Sep 25, 2026

Microsoft, Nike, Nektar Therapeutics - TradingView

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar Therapeutics Wins $90M Lilly Verdict - grafa.com

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar Therapeutics stock rises on $90M jury verdict vs Lilly - Investing.com

Sep 25, 2026
pulisher
Sep 25, 2026

Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord

Sep 25, 2026
pulisher
Sep 25, 2026

Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - Dealroom

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar prevails in legal battle with Lilly over broken rezpeg partnership - BioSpace

Sep 25, 2026
pulisher
Sep 25, 2026

Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal - Yahoo Finance

Sep 25, 2026
pulisher
Sep 25, 2026

Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - Benzinga

Sep 25, 2026
pulisher
Sep 25, 2026

BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target - TradingView

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update - Morningstar

Sep 25, 2026
pulisher
Sep 25, 2026

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data - Yahoo Finance

Sep 25, 2026
pulisher
Sep 25, 2026

Why is Nektar Therapeutics stock climbing today? - Investing.com

Sep 25, 2026
pulisher
Sep 25, 2026

Form 8K Nektar Therapeutics For: 25 September By Investing.com - Investing.com India

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar gains 5% as jury awards $90M plus interest in Lilly trial - TradingView

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute - TradingView

Sep 25, 2026
pulisher
Sep 25, 2026

Nektar TherapeuticsJury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement - TradingView

Sep 25, 2026
pulisher
Sep 24, 2026

Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - law360.com

Sep 24, 2026
pulisher
Sep 24, 2026

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Sep 24, 2026
pulisher
Sep 24, 2026

Nektar Therapeutics stock gains 2.98 percent on trial watch - AD HOC NEWS

Sep 24, 2026
pulisher
Sep 23, 2026

Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target - TradingView

Sep 23, 2026
pulisher
Sep 23, 2026

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits

Sep 23, 2026
pulisher
Sep 22, 2026

Nektar Therapeutics stock falls 9.6 percent as patent case weighs - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 22, 2026

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com

Sep 22, 2026
pulisher
Sep 22, 2026

Nektar Therapeutics drops as jury deliberates in Eli Lilly dispute over Rezpeg - TradingView

Sep 22, 2026
pulisher
Sep 22, 2026

How Investors Are Reacting To Nektar Therapeutics (NKTR) Index Reclassification - simplywall.st

Sep 22, 2026
pulisher
Sep 20, 2026

Nektar Therapeutics(NasdaqCM: NKTR) added to S&P Biotechnology Select Industry Index - marketscreener.com

Sep 20, 2026
pulisher
Sep 20, 2026

Nektar Therapeutics(NasdaqCM:NKTR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com

Sep 20, 2026
pulisher
Sep 19, 2026

Nektar Therapeutics (NKTR), What Is Drawing Fresh Attention Now? - simplywall.st

Sep 19, 2026
pulisher
Sep 18, 2026

Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End - law360.com

Sep 18, 2026
pulisher
Sep 18, 2026

Nektar Therapeutics stock gains after Q2 loss narrows - AD HOC NEWS

Sep 18, 2026
pulisher
Sep 17, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire

Sep 17, 2026
pulisher
Sep 15, 2026

Nektar Therapeutics options flow shows bullish bets against a bearish tape - Investing.com

Sep 15, 2026
pulisher
Sep 15, 2026

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress

Sep 15, 2026
pulisher
Sep 10, 2026

Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told - Law360

Sep 10, 2026
pulisher
Sep 09, 2026

Nektar CEO Opens Door To Finance Questions In Eli Lilly Trial - Law360

Sep 09, 2026
pulisher
Sep 09, 2026

Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata - The Clinical Trial Vanguard

Sep 09, 2026
pulisher
Sep 08, 2026

Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360

Sep 08, 2026
pulisher
Sep 07, 2026

Lancet Phase 2b REZOLVE-AD Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st

Sep 07, 2026
pulisher
Sep 07, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire

Sep 07, 2026
pulisher
Sep 06, 2026

Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In? - simplywall.st

Sep 06, 2026
pulisher
Sep 06, 2026

2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | NDAQ:NKTR | Press Release - stockhouse.com

Sep 06, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):